Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

RETA GLP-3Understand the science

How two retatrutide trials counted breathing interruptions during sleep

3 numbered sourcesSource years 2025, 2026

Peptides are short chains of amino acids held together by peptide bonds. Researchers can modify a chain so it activates several receptors involved in metabolism. Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. “RETA GLP-3” is a catalog label. Its number does not name a receptor target. A 2026 report examined retatrutide in adults with moderate to severe obstructive sleep apnea. [1, 2]

The study reported two randomized, double-blind comparisons within the larger TRIUMPH program. One included people without type 2 diabetes and the other included people with it. All participants in these sleep apnea comparisons had a body mass index of at least 27 and moderate to severe obstructive sleep apnea. The researchers assigned people to retatrutide or placebo and assessed breathing at 80 weeks. There were 243 randomized participants in the first comparison and 448 in the second. [1]

The main measure was the apnea-hypopnea index, the average number of times per hour of sleep that breathing stopped or decreased enough to meet the study definition. In the trial without diabetes, average reductions in the two principal active groups were about 34 and 32 events per hour, compared with about 10 with placebo. In the trial with type 2 diabetes, the corresponding reductions were about 25 events per hour in both principal active groups and 10 with placebo. These values come from the authors’ main statistical analysis. [1]

The analysis applied different assumptions depending on events that occurred after people were assigned to treatment. For specified events suggesting treatment failure, it estimated results under a hypothetical scenario. It used a treatment-policy approach for other events. The authors also reported results based on intention to treat. Seeing both sets of results helps readers understand what the researchers assumed when estimating changes in participants’ breathing. [1]

The comparisons tell us about the frequency of interrupted breathing in a particular population over the tested period. Those counts do not describe every feature of sleep, oxygen levels or daytime function. The sleep apnea analyses were also nested in the larger TRIUMPH program, so their data overlap with reports from the parent trials. They should not be counted as independent replications of the parent trial results. The intervention remains investigational. The result in these participants is evidence about the tested formulation under trial conditions, while any regulatory indication would be a separate decision. [1, 2, 3]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop RETA GLP-3

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.